"Designing Growth Strategies is in our DNA"
Region : Global | Published Date: Upcoming | Report ID: FBI101279| Status : Pipeline
Clostridium difficile, also referred to as C. difficile or C. diff is a bacterium that can induce a range of symptoms including diarrhea to the life-threatening inflammation of the colon. Clostridium difficile infections generally occur in elderly adults residing in hospitals or in long term care facilities and typically occurs after the administration of antibiotic medications. Recent studies have shown the increased risk of clostridium difficile infections in younger and healthy populations without any prior history of exposure to healthcare institutions or antibiotic usage.
Some of the symptoms associated with clostridium difficile infections include diarrhea of more than 10 times a day, severe abdominal cramping, fever, loss of appetite, dehydration and rapid heartbeat. The diagnosis of clostridium difficile is often undertaken with stool tests which include enzyme immunoassay, polymerase chain reaction and cell cytotoxicity assays. The treatment of these infections is often conducted by the administration of antibiotics such as metronidazole, vancomycin, and fidaxomicin.
Pharmaceutical companies along with various research institutes have been focusing on studying and developing new treatment options for clostridium difficile infections (clostridium difficile associated disease). For instance; RBX2660, which is being studied by Rebiotix Inc., is currently in phase-3 clinical trials for the microbiota restoration therapy for recurrent clostridium difficile infection (PUNCH CD3-OLS) (CD3-OLS).
To get details on market share, speak to our analyst
At present around 75% of the pipeline candidates for clostridium difficile infections (clostridium difficile associated disease) are in the phase-2 and phase-3 stage combined. More than half of the studies are sponsored by industry.
The report on ‘Clostridium Difficile Infections (Clostridium Difficile Associated Disease) – Pipeline Review, 2019’ provides a comprehensive overview of the drugs that are in the R&D pipeline by indication or molecule for Clostridium Difficile Infections (Clostridium Difficile Associated Disease). The report provides a thorough analysis of the distribution of the pipeline products by clinical trial stage, indication, company, therapy area and details such as clinical trial stage, sponsor, description on every product in the pipeline. Products in the preclinical and clinical stage along with dormant & discontinued pipeline candidates are included in the report. The report also covers additional insights such as epidemiology overview and current market scenario for Clostridium Difficile Infections (Clostridium Difficile Associated Disease).
The report on ‘Clostridium Difficile Infections (Clostridium Difficile Associated Disease) – Pipeline Review, 2019’, which is built by following a robust research methodology involving primary interviews and desk research, provides a complete overview of the R&D activity and pipeline products to assist companies in developing growth strategies and identifying emerging players.